Skip to main content

Advertisement

Log in

Interleukin-31: A Novel Diagnostic Marker of Allergic Diseases

  • BASIC AND APPLIED SCIENCE (M FRIERI AND PJ BRYCE, SECTION EDITORS)
  • Published:
Current Allergy and Asthma Reports Aims and scope Submit manuscript

Abstract

Interleukin-31 (IL-31) is a newly discovered cytokine associated with chronic skin inflammation and pruritus. Patients with atopic dermatitis, chronic spontaneous urticaria, allergic contact dermatitis, prurigo nodularis, primary cutaneous lymphoma and mastocytosis exhibit increased serum levels of IL-31 protein and elevated IL-31 mRNA in the skin. Interestingly, in some of these diseases, IL-31 serum levels correlate with disease activity. In the present review, we particularly focus on studies investigating IL-31 as a novel diagnostic biomarker indicating the severity of allergic diseases. We highlight a recent study on IL-31 in mastocytosis, which reports on elevated serum levels of IL-31 in adults correlating with the severity of disease categories, tryptase levels and percentage of bone marrow infiltration. We conclude that growing knowledge about IL-31, its receptors and signaling pathways serves to better understand the pathogenesis of allergic diseases and may lead to the development of novel treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Dillon SR et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5(7):752–60.

    Article  PubMed  CAS  Google Scholar 

  2. Cornelissen C et al. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91(6-7):552–66. This review provides an excellent summary of IL-31 structure and function.

    Article  PubMed  CAS  Google Scholar 

  3. Chen Q, Carroll HP, Gadina M. The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm. 2006;74:207–28.

    Article  PubMed  CAS  Google Scholar 

  4. Zhang Q et al. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19(5–6):347–56.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Andoh A et al. Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol. 2008;14(33):5154–61.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  6. Yagi Y et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med. 2007;19(6):941–6.

    PubMed  CAS  Google Scholar 

  7. Baumann, R., et al., The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. Clin Transl Allergy, 2012. 2(1): p. 2045-7022. This paper shows that IL-31 is not only important in the skin; after nasal challenge it is released into nasal secretions in patients with allergic rhinitis

  8. Sonkoly E et al. IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–7.

    Article  PubMed  CAS  Google Scholar 

  9. Schulz F et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol. 2007;120(5):1097–102.

    Article  PubMed  CAS  Google Scholar 

  10. Nagy N et al. Common IL-31 gene haplotype associated with non-atopic eczema is not implicated in epidermolysis bullosa pruriginosa. Acta Derm Venereol. 2010;90(6):631–2.

    Article  PubMed  Google Scholar 

  11. Lan C-CE et al. Distinct SPINK5 and IL-31 polymorphisms are associated with atopic eczema and non-atopic hand dermatitis in Taiwanese nursing population. Exp Dermatol. 2011;20(12):975–9.

    Article  PubMed  CAS  Google Scholar 

  12. Yu JI et al. Identifying Polymorphisms in IL-31 and Their Association with Susceptibility to Asthma. Korean J Pathol. 2012;46(2):162–8.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Sokolowska-Wojdylo M et al. Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis. J Eur Acad Dermatol Venereol. 2013;27(5):662–4.

    Article  PubMed  CAS  Google Scholar 

  14. Bilsborough J et al. IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006;117(2):418–25.

    Article  PubMed  CAS  Google Scholar 

  15. Cheung PF et al. Activation of human eosinophils and epidermal keratinocytes by Th2 cytokine IL-31: implication for the immunopathogenesis of atopic dermatitis. Int Immunol. 2010;22(6):453–67.

    Article  PubMed  CAS  Google Scholar 

  16. Wong CK et al. Activation of eosinophils interacting with dermal fibroblasts by pruritogenic cytokine IL-31 and alarmin IL-33: implications in atopic dermatitis. PLoS ONE. 2012;7(1):17.

    Google Scholar 

  17. Cornelissen C et al. Ultraviolet B radiation and reactive oxygen species modulate interleukin-31 expression in T lymphocytes, monocytes and dendritic cells. Br J Dermatol. 2011;165(5):966–75.

    Article  PubMed  CAS  Google Scholar 

  18. Kasraie S et al. Functional effects of interleukin 31 in human primary keratinocytes. Allergy. 2011;66(7):845–52.

    Article  PubMed  CAS  Google Scholar 

  19. Stott B et al. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol. 2013;132(2):446–54.

    Article  PubMed  CAS  Google Scholar 

  20. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2010;65(6):712–21.

    Article  PubMed  CAS  Google Scholar 

  21. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 activates signal transducer and activator of transcription (STAT)-1, STAT-5 and extracellular signal-regulated kinase 1/2 and down-regulates IL-12p40 production in activated human macrophages. Allergy. 2013;68(6):739–47.

    Article  PubMed  CAS  Google Scholar 

  22. Ishii T et al. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009;113(23):5942–50.

    PubMed  CAS  Google Scholar 

  23. Niyonsaba F et al. Antimicrobial Peptides Human β-Defensins and Cathelicidin LL-37 Induce the Secretion of a Pruritogenic Cytokine IL-31 by Human Mast Cells. J Immunol. 2010;184(7):3526–34.

    Article  PubMed  CAS  Google Scholar 

  24. Escribano L et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514–21.

    Article  PubMed  Google Scholar 

  25. Frieri M, Patel R, Celestin J. Mast cell activation syndrome: a review. Curr Allergy Asthma Rep. 2013;13(1):27–32.

    Article  PubMed  CAS  Google Scholar 

  26. Frieri M, Quershi M. Pediatric Mastocytosis: A Review of the Literature. Pediatr Allergy Immunol Pulmonol. 2013;26(4):175–80.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Hartmann, K., et al., Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol, 2013. 132(1): p. 232-235.e4. This study is the first to describe altered serum levels of IL-31 in patients with mastocytosis.

  28. Lee CH, Yu HS. Biomarkers for itch and disease severity in atopic dermatitis. Curr Probl Dermatol. 2011;41:136–48.

    Article  PubMed  CAS  Google Scholar 

  29. Neis MM et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol. 2006;118(4):930–7.

    Article  PubMed  CAS  Google Scholar 

  30. Raap U et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122(2):421–3.

    Article  PubMed  CAS  Google Scholar 

  31. Incorvaia C et al. Allergy and the skin. Clin Exp Immunol. 2008;1:27–9.

    Article  CAS  Google Scholar 

  32. Kim S et al. IL-31 Serum Protein and Tissue mRNA Levels in Patients with Atopic Dermatitis. Ann Dermatol. 2011;23(4):468–73.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  33. Niebuhr M et al. Staphylococcal alpha-toxin induces a higher T cell proliferation and interleukin-31 in atopic dermatitis. Int Arch Allergy Immunol. 2011;156(4):412–5.

    Article  PubMed  CAS  Google Scholar 

  34. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. J Eur Acad Dermatol Venereol. 2011;25(3):334–9.

    Article  PubMed  CAS  Google Scholar 

  35. Nobbe S et al. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012;92(1):24–8.

    Article  PubMed  CAS  Google Scholar 

  36. Szegedi K et al. Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol. 2012;21(6):431–6.

    Article  PubMed  CAS  Google Scholar 

  37. Hawro, T., et al., Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy, 2013. 20(10): p. 12316. This article nicely shows that IL-31 does not induce an immediate itch response in humans.

  38. Ohmatsu, H., et al., Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol, 2012. 92(3): p. 282-3. An excellent study providing new insights into the role of IL-31 in cutaneous T-cell lymphoma.

  39. Takaoka A et al. Expression of IL-31 gene transcripts in NC/Nga mice with atopic dermatitis. Eur J Pharmacol. 2005;516(2):180–1.

    Article  PubMed  CAS  Google Scholar 

  40. Singer EM et al. IL-31 Is Produced by the Malignant T-Cell Population in Cutaneous T-Cell Lymphoma and Correlates with CTCL Pruritus. J Invest Dermatol. 2013;133(12):2783–5.

    Article  PubMed  CAS  Google Scholar 

  41. Raap U et al. Increased levels of serum IL-31 in chronic spontaneous urticaria. Exp Dermatol. 2010;19(5):464–6.

    Article  PubMed  CAS  Google Scholar 

  42. Narbutt J et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res. 2013;305(3):191–5.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  43. Zhang M et al. Serum levels of cytokines in systemic lupus erythematosus : Association study in a Chinese population. Z Rheumatol. 2013;7:1–4.

    CAS  Google Scholar 

  44. Park K et al. Increased expression of mRNAs for IL-4, IL-17, IL-22 and IL-31 in skin lesions of subacute and chronic forms of prurigo. Eur J Dermatol. 2011;21(1):135–6.

    PubMed  Google Scholar 

  45. Shiao YM et al. MCP-1 as an effector of IL-31 signaling in familial primary cutaneous amyloidosis. J Invest Dermatol. 2013;133(5):1375–8.

    Article  PubMed  CAS  Google Scholar 

  46. Cornelissen C et al. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2):426–33.

    Article  PubMed  CAS  Google Scholar 

  47. Grimstad Ø et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol. 2009;18(1):35–43.

    Article  PubMed  CAS  Google Scholar 

  48. Shah SA et al. Effects of interleukin-31 on MUC5AC gene expression in nasal allergic inflammation. Pharmacology. 2013;91(3–4):158–64.

    Article  PubMed  CAS  Google Scholar 

  49. Okano M et al. Characterization of pollen antigen-induced IL-31 production by PBMCs in patients with allergic rhinitis. J Allergy Clin Immunol. 2011;127(1):277–9.

    Article  PubMed  CAS  Google Scholar 

  50. Lei Z et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy. 2008;63(3):327–32.

    Article  PubMed  CAS  Google Scholar 

  51. Ip WK et al. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007;122(4):532–41.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  52. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483–94.

    Article  PubMed  CAS  Google Scholar 

  53. Arai, I., et al., A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behaviour in mice. Exp Dermatol, 2013. 22(10): p. 669-71. Interesting murine study about IL-31-induced itch-associated scratching behavior.

  54. Gonzales AJ et al. Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis. Vet Dermatol. 2013;24(1):48–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by research grants from the German Research Council (DFG; CRC/SFB832, project A14), the German-Israeli Foundation for Scientific Research and Development (993/2008) and the Wilhelm Sander Foundation (1999.049.2) to Karin Hartmann.

Compliance with Ethics Guidelines

Conflict of Interest

Karin Hartmann has served as a speaker for ALK-Abello, Novartis and Shire; is a consultant in a Novartis trial; and has received research grants from Novartis.

Anja Rabenhorst declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karin Hartmann.

Additional information

This article is part of the Topical Collection on Basic and Applied Science

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rabenhorst, A., Hartmann, K. Interleukin-31: A Novel Diagnostic Marker of Allergic Diseases. Curr Allergy Asthma Rep 14, 423 (2014). https://doi.org/10.1007/s11882-014-0423-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11882-014-0423-y

Keywords

Navigation